A system for targeting foreign DNA to epithelial cells in vitro has been developed by exploiting receptor-mediated endocytosis. The polymeric immunoglobulin receptor transports dimeric immunoglobulin A and immunoglobulin M through epithelial cells, including those of the respiratory tract, by binding the immunoglobulins at the basolateral surface and transporting them across the cell. Fab fragments of antibodies directed against the extracellular portion of the receptor, secretory component, are similarly transported. Anti-human secretory component Fab fragments were covalently linked to a polycation, and complexed to various expression plasmids. When bound to an expression plasmid containing the Escherichia col lacZ gene ligated to the Rous sarcoma virus promoter, the complexes transfected HT29.74 human colon carcinoma cells induced to express polymeric immunoglobulin receptor, but not those lacking the receptor. Primary cultures of human tracheal epithelial cells grown on collagen gels, which induce the expression of polymeric immunoglobulin receptor, were also transfected with the complexes. From 5 to 66% of the respiratory epithelial cells had fl-galactosidase activity after treatment, comparable to the percentage of cultured human tracheal epithelial cells that express polymeric immunoglobulin receptor (8-35%). The addition of excess human secretory component (Fab ligand) to the culture medium at the time of transfection blocked the delivery of DNA. The expression plasmid, either alone, complexed to the polycation, or complexed to a carrier based on an irrelevant Fab fragment, was not effective in transfecting either cell type. This DNA carrier system introduces DNA specifically into epithelial cells that contain pIgR in vitro. (J. Clin. Invest. 1993.92:2394-2400
Introduction
In cystic fibrosis (CF),' the most common lethal genetic disease of Caucasians, the defective function of the cystic fibrosis transmembrane conductance regulator (CFTR) in airway epithelial cells and submucosal glands results in chronic, suppura-tive pulmonary disease, usually leading to death. Because CF is an autosomal recessive disorder, gene augmentation could theoretically correct the defect provided that methods of delivering normal copies of CFTR to affected cells are safe, efficient, and selective.
Replication deficient, recombinant adenoviruses have been used to deliver genes to respiratory epithelial cells ( 1, 2) . Although this method ofgene transfer has considerable appeal for its efficiency, adenoviruses may lack sufficient cell selectivity in vivo. The physiologic effects of treatment with adenovirus are unknown. Furthermore, concerns have arisen that the disabled viral vectors might become activated following infection and produce replication-competent virus (3) . Adeno-associated virus (4, 5) and recombinant retroviruses (6, 7) have also been proposed as vectors for introducing genes into the respiratory tract, but both systems have had significant practical limitations (3) . Mechanical techniques ofgene transfer, like lipofection (8) (9) (10) , may have substantial cytotoxicity and lack specificity. Receptor-mediated gene transfer, however, affords specificity in the context of a noninfectious vector.
The polymeric immunoglobulin receptor (pIgR) is expressed only in human mucosal epithelial cells, including airway epithelial cells, submucosal gland cells, and intestinal cells. It is specifically adapted for the internalization of large molecules, including noncovalent complexes of immunoglobulin A (IgA) and antigen, by endocytosis( 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . This receptortherefore appears to be an ideal candidate for receptor-mediated gene transfer. We tested this hypothesis by examining the ability of pIgR to deliver functional exogenous genes to human intestinal and tracheal epithelial cells that express the receptor. MO) , and N-succinimidyl-3-(2-pyridyldithio)proprionate was purchased from Pierce Chemical Company (Rockford, IL). All media, sera, and antibiotics were obtained from Gibco Laboratories (Grand Island, NY).
Preparation of Fab fragments. Antisera were raised in rabbits against secretory component purified from human colostrum. The an-1. Abbreviations used in this paper: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ONPG, o-nitrophenyl l-D-galactopyranoside; pIgR, polymeric immunoglobulin receptor; SC, secretory component; SPDP, N-succinimidyl 3-(2-pyridyldithio)-proprionate; X-gal, 5-bromo-4-chloro-3-indolyl-/3-galactopyranoside.
tibody recognizes purified secretory component (SC), secretory IgA, and the polymeric immunoglobulin receptor, but not dimeric IgA ( 15) . The antibody was isolated using a Protein A MAPS agarose column as described by the manufacturer, and was subjected to cleavage by insoluble papain attached to agarose beads. Briefly, 2 mg of isolated immunoglobulin G (IgG) was treated with 20 ,g papain for 12 h at 370C in the presence of 100 mM sodium acetate, pH 5.5, 50 mM cysteine, and 1 mM EDTA. The Fab fragment was separated from intact antibody and Fc fragments by Protein A chromatography. An irrelevant Fab was also generated by papain digestion of IgG from preimmune rabbit serum.
Preparation ofFab-polylysine conjugates. The Fab fragment ofthe anti-pIgR immunoglobulin G was covalently linked to poly (L-lysine) (M, 20,000 D) using the heterobifunctional crosslinking reagent Nsuccinimidyl 3-(2-pyridyldithio) proprionate (SPDP). The Fab fragment was incubated with a fifteenfold molar excess of SPDP in 0. l M PBS, pH 7.5, at 220C for 60 min. After introduction of 2-pyridyl disulfide structures onto the Fab fragment, unreacted SPDP and low molecular weight reaction products were removed by dialysis. The disulfide bridges of the modified Fab fragment were cleaved with 25 mM DTT, pH 4.5. Fifteenfold molar excess of poly (L-lysine) and SPDP was added to the modified Fab fragment, and the reaction was carried out at 22°C for 24 h. The conjugate was dialyzed to remove low molecular weight reaction products, and analyzed by separating the resultant proteins on a 0.1% SDS-7.5% polyacrylamide gel electrophoresis. Gels were stained with Coomassie brilliant blue for 2 h, and subsequently destained for 24 h with a solution containing 30% methanol and 10% acetic acid. Analysis of different preparations demonstrated a protein that migrated slowly, corresponding to a protein greater than 200 kD in size (data not shown). This slow migration is most likely due to the high proportion of basic amino acids, i.e., lysine, attached to the Fab fragment. A small fraction of the Fab portion did not bind to the poly (L-lysine), as evidenced by the presence of a 50-kD protein, the expected size of the fragment.
Reporter genes andplasmidpreparation. The plasmids pRSVZ and pRSVCAT, consisting of the Escherichia coli lacZ and chloramphenicol acetyltransferase genes, respectively, ligated to the Rous sarcoma virus long terminal repeat promoter inserted into a modified pBR322 vector, were used as reporter genes. The plasmids were grown in E. coli DH5a, extracted, and purified by standard techniques ( 14 harvested from necropsy specimens less than 24 h postmortem using a modification ofthe procedure described by Wu (16) and cultured (11) as previously described. Cells were grown on collagen gel matrices (11, 17) (22) . The optical density of the samples was measured at 420 nm.
Individual cells expressing f3-galactosidase were also identified following incubation with X-gal as described previously (22 (Fig. 1 b) . Expression occurred 48 h after transfection, when the plasmid and carrier were combined in 1:16 molar ratio. Optimal transfection was achieved with this DNA:carrier ratio at 96 h. Expression had vanished by 120 h after transfection. The carrier delivered DNA to 5-10% of HT29.74 cells, which had been grown in glucose-free media and treated with human IFNa, as compared to < 3% of cells grown in glucose (data not shown). Rare cells treated with either the conjugate or DNA alone were also blue stained, most likely due to an endogenous fl-galactosidase. Nevertheless, the percentage of blue stained cells in the controls was significantly less than that in the transfected dishes.
Transfection of human tracheal epithelial cells. We have previously shown that human tracheal epithelial cells grown on plastic down-regulate the expression of pIgR, whereas cells grown on collagen gels maintain production (9) . To estimate the proportion of cells grown on collagen that express the receptor, two strategies were used. First, after demonstrating that collagenase does not affect the pIgR immunoreactivity (9), the cells were released from the collagen support enzymatically, stained with antibody directed against the receptor and antirabbit FITC, and counted in a fluorescence activated cell sorter (FACS® (Fig. 2) . Cells that did not express pIgR were not transfected. We compared tracheal epithelial cells grown on plastic to cells grown on collagen gels in two separate experiments. In both instances, the percentage of blue stained cells grown on plastic was comparable to nontransfected controls (mean 2.5%), whereas a mean of 6% of the cells maintained on collagen gels were positive in this particular experiment (data not shown). Treatment ofthe complexes with DTT, which cleaves the crosslinking, disulfide bonds of the Fab-polylysine carrier, completely eliminated uptake and expression of the reporter gene. Addition of a fourfold molar excess of dimeric IgA over complex to the culture media failed to reduce uptake by competing for available pIgR. No significant change in the proportion of cells expressing the reporter gene was noted (Table I) . However, incubation with a fourfold molar excess of secretory component, the soluble extracellular domain of pIgR, which reacts with the anti-pIgR Fab fragment, completely inhibited the uptake and expression of the reporter gene (Table I) .
,B-galactosidase assays demonstrated a twofold excess of ac- (Fig. 3) .
Discussion
Expression plasmids noncovalently bound to the Fab fragment of antibody directed against the polymeric immunoglobulin receptor (pIgR) can be introduced efficiently into cells that express the receptor. Delivery is specific for cells that express pIgR, since human tracheal epithelial cells grown on plastic, a condition that down-regulates the expression of the receptor, fail to express the reporter gene whereas cells from the same trachea maintained on collagen gels can be transfected. The transfection of HT29.74 cells was also dependent on the level of expression of pIgR, since cells grown in conditions that upregulate the receptor express the reporter gene more than cells grown in undifferentiating conditions. Delivery of DNA is inhibited by excess secretory component in the medium, which presumably occupies the recognition site on the Fab fragment, preventing its interaction with the receptor. However, competition for the pIgR with dimeric IgA in a fourfold molar excess failed to block the delivery of the complex, perhaps indicating that the binding site(s) on the pIgR for dimeric IgA and anti-SC do not overlap. Alternatively, the natural ligand may not compete effectively with the anti-SC for the receptor, or the receptor may be present in excess. Uptake is not due to a nonspecific increase in pinocytosis secondary to the presence ofthe Fab fragment in the culture medium, for the addition of Fab fragments with uncomplexed DNA or the carrier-DNA complex after dissociation with DTT does not result in an increase in reporter gene expression. Moreover, the use of complexes with Fab fragments from irrelevant antibodies did not permit the uptake and expression of the reporter gene. Thus, the uptake and expression of the reporter gene is mediated by the specific interaction of the complex with pIgR. The specificity ofgene transfer in vitro for cells that bear the pIgR as well as the success of gene transfer in the presence of the natural ligand for the receptor permits speculation as to whether this strategy might be useful in delivering genes into the defective cells in the bronchi and bronchioles of patients with cystic fibrosis. In humans, the pIgR is expressed in airway epithelial cells that reach the luminal surface and in cells ofthe submucosal glands, especially serous cells ( 11) . This distribution conforms to that of CFTR in the airway. The pIgR is expressed in human fetuses from the 16th gestational wk (25), secretory component has been found in tracheal aspirates from premature neonates (26) , and patients with cystic fibrosis express this protein at normal or, in some instances, at elevated levels (27). Furthermore, the anti-SC provides greater specificity for the targeted cells than the natural ligand dimeric IgA, which can bind to alternative receptors (e.g., Fc receptors) on other cell types. Specific targeting of these cells may be of importance for gene therapy of cystic fibrosis, because the indiscriminate insertion of cAMP-regulated chloride channels into many cell types may be undesirable. In addition, the expense of producing large quantities of DNA and vector, in excess of what is necessary for the physiologic correction ofthe defect in target cells, could make nonselective gene transfer impractical. Thus, targeting this receptor may be a potential method of introducing normal copies of the CFTR gene into respiratory cells in patients with cystic fibrosis. However, because the pIgR is asymmetrically distributed, predominantly on the basolateral surface of epithelial cells, the complex would need to be delivered via injection into the systemic circulation. This route may not be practical due to the endothelial cell barriers to egress of the complex from the blood to the underlying tissue. Even if the proper cells could be targeted, the extent and level of expression of the transgene would need to be sufficient for the treatment of cystic fibrosis. The proportion of cells that must undergo genetic correction to achieve electrophysiologic correction of human tracheal epithelial cells in monolayer culture has been estimated to be as low as 6% (28), a level achievable in vitro by this method ofgene transfer. A variable percentage of primary human tracheal epithelial cells in culture were transfected via the pIgR. The sources of variability ofthis gene transfer system are not entirely clear at the present time, but could reside either in the complex or with the target cells. Although the complexes were produced using the same procedure each time, the amount of free carrier or unbound plasmid present in the sample could vary and contribute to the differences in uptake. However, it seems more likely that the differences in pIgR expression in the cultured cells will account for most of the observed variation. The proportion of human tracheal epithelial cells in culture that express pIgR, which is detectable by immunofluorescence, ranges from 8-35%, compared to 5-66% of the cells that express the reporter gene delivered by the carrier, so it may be that the majority of cells in culture that actually express pIgR are transfected. In fact, the expression of the reporter gene was co-localized to cells that expressed the pIgR, as identified by immunohistochemical means. Consequently, this technique could potentially be useful in vivo, where the majority of the airway epithelial cells and serous cells of the submucosal glands express pIgR (1 1, 27, 29) .
The level of expression of the reporter genes in the system in vitro was low. In order to detect the blue color characteristic of 3-galactosidase in transfected cells, the preparations required prolonged incubations with the reagents, and even so, the staining was not intense. Quantitative in vitro enzymatic assays showed only low levels of (-galactosidase or chloramphenicol acetyltransferase expression. Expression of genes introduced by receptor-mediated mechanisms may be limited by the trapping and degradation of the complex in endosomal compartments (30, 31 ) , or, in the case of pIgR, the complex may undergo transcytosis and be discharged from the cell complexed with secretory component. However, the level of expression necessary for gene transfer to be therapeutic will greatly depend on the disorder being treated. For example, the level of CFTR expression required in airway cells for functional correction of the defect may be quite low. The CFTR protein is difficult to detect histochemically (32) , and mRNA transcripts are not abundant in airway cells (33) . Individuals who are heterozygous for CF are phenotypically normal and their pulmonary function is unimpaired, thus half the normal complement of CFTR is adequate. Moreover, phenotypically normal humans have been identified who express an alternatively spliced, inactive form that accounts for as high as 92% of the total CFTR mRNA (34) . Therefore, low levels of expression of normal CFTR directed by a transferred exogenous gene may be sufficient for functional correction of the genetic defect.
In summary, the spatial distribution of the pIgR and specificity ofgene delivery using the described method may be favorable for gene therapy. The level of transgene expression Figure 2 . Photomicrographs of human tracheal epithelial cells transfected with pRSVZ using the Fab-polylysine carrier. 10 ,g of pRSVZ were complexed to the carrier and applied to primary human tracheal epithelial cells grown on a collagen gel matrix. After 48 h, the cells were stained with a solution containing 0.5% X-gal as described in Methods. In addition, the cells were also analyzed for the presence of the pIgR by indirect achieved by this system may also be sufficient for the correction of the CF defect. However, access to the receptor on the basolateral surface of respiratory epithelial cells in vivo may pose formidable problems in developing of this technique for practical use. The use of antibodies as the ligand for receptor mediated gene transfer has been successful in the case of pIgR, and may be applicable to other receptors that undergo internalization. Antibodies, or their Fab fragments, may enhance specificity, since naturally occurring ligands may interact with multiple receptors. In some instances, the natural ligand may be unsuitable for conjugation to a polycation like poly (L-lysine), whereas antibodies can be used for this purpose. Even if the target receptor has not been purified, thus precluding the production ofspecific antibodies against it, antiidiotype antibodies could be constructed to mimic the structure of the natural ligand. Because internalization ofsurface receptors appears to be a ubiquitous regulatory mechanism or cellular response, many classes of receptors could potentially be used as a "Trojan horse" to introduce the gene of interest into the cell.
